Novel non-HDLc/HDLc ratio for predicting MASLD: a cross-sectional study in a Chinese health screening population Authors: Yan Hong, Xinrong Chen, Hangtao Yuan, Zixuan Huang, Shaohong Tao, Fang Xie, Weining Xie Published: 2024 ABSTRACT BackgroundPrevious studies have shown a positive correlation between the non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol(non-HDLc/HDLc ratio) and metabolism-associated steatohepatitis (MASLD), suggesting it is a superior predictor of MASLD.The aim of this study is to assess the predictive value of the non-HDLc/HDLc ratio for MASLD.MethodsIn this study, we retrospectively analyzed data from 4,498 adult patients at the Health Management Centre of Guangdong Provincial Hospital of Integrative Medicine, regardless of gender, and the diagnostic criteria for MASLD were derived from guidelines. We used univariate and multivariate logistic regression to verify the relationship between the non-HDLc/HDLc ratio and MASLD and assessed the stability of the results through interaction tests. ROC curve analysis was then employed to compare the diagnostic efficacy of several lipid indices, including the non-HDLc/HDLc ratio, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), and the composite lipid profile in diagnosing MASLD.ResultsThese data suggested that non-HDLc/HDLc, LDL-C, TG, and TC were positively correlated with MASLD, while HDL-C was inversely correlated, even after adjusting for confounders such as gender, age, body mass index, ALT, AST, uric acid, blood glucose, and hypertension. Among them, non-HDLc/HDLc ratio(OR: 2.709, 95% CI: 2.316–3.169, p < 0.001), LDL-C (OR: 1.294, 95% CI: 1.125–1.489, p < 0.001), TG (OR: 2.854, 95% CI: 2.473–3.293, p < 0.001), TC (OR: 1.242, 95% CI: 1.122–1.374, p < 0.001), and HDL-C (OR: 0.074, 95% CI: 0.044–0.123, p < 0.001) were identified. The interaction results showed that gender did not affect lipid levels in MASLD (p > 0.05). ROC analysis confirmed the validity of the non-HDL cholesterol/HDL cholesterol ratio in predicting MASLD incidence, with an AUC of 0.801. Moreover, the composite lipid indices demonstrated greater predictive power for MASLD compared to individual indices (AUC: 0.857), and validation set results were consistent with those of the training set.ConclusionThe present study revealed that the non-HDLc/HDLc ratio was positively correlated with the development of MASLD, and the ratio was also effective in predicting MASLD.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12876-024-03525-z. Introduction Nonalcoholic Fatty Liver Disease (NAFLD) is among the most prevalent chronic liver diseases (CLD) worldwide, with an estimated prevalence of approximately 30% [1]. It is becoming increasingly prevalent as a chronic liver disease, superseding viral hepatitis in this regard [2]. Recent studies indicate that the prevalence of NAFLD is exacerbated by increasing rates of obesity and metabolic syndrome(MS) [3]. Insulin resistance and metabolic disorders play a pivotal role in the pathogenesis of NAFLD and its associated intrahepatic and extrahepatic complications. NAFLD is increasingly acknowledged as a multisystemic disease associated with metabolic function [4–6].In 2023, the Liver Association formally proposed replacing the term ‘NAFLD’ with ‘Metabolic Dysfunction-Associated Steatohepatopathy (MASLD) as the official nomenclature for this condition [7]In addition to reflecting the pathophysiology of liver disease, MASLD is closely linked to cardiac metabolism and is recognized as a risk factor for major adverse cardiovascular events and mortality [8, 9].Therefore, early identification and timely intervention are essential for mitigating the progression of both liver and cardiovascular diseases associated with MASLD. Common dyslipidemias associated with MASLD include elevated levels of LDL cholestero (LDL-C), triglycerides(TG), and total cholesterol(TC), as well as decreased levels of HDL-C. Dyslipidemia is commonly classified into four principal types: hypercholesterolemia, hypertriglyceridemia, low HDL-C, and mixed dyslipidemia. Factors such as obesity, an unhealthy diet, diabetes mellitus, and kidney disease may contribute to an abnormal increase in blood lipid levels, potentially leading to hyperlipidemia [10, 11]. Hyperlipidemia is often identified through physical examinations or screenings for comorbidities, given its lack of distinctive clinical manifestations. The condition is defined by a serum LDL-C concentration of ≥ 130 mg/dL, TC concentration of ≥ 200 mg/dL, TG concentration of ≥ 150 mg/dL, or a HDL concentration of ≤ 50 mg/dL in women and ≤ 40 mg/dL in men. Patients diagnosed with hyperlipidemia are generally advised to modify their diet, engage in regular exercise, and receive pharmacological treatment with lipid-lowering medications. But, the incidence of hyperlipidaemia and the emergence of complications are rising in parallel with rapid societal development and improvements in living standards. A novel lipid profile index, the ratio of non-HDLc/HDLc, has been recently developed. Non-HDLc encompasses all potentially atherogenic cholesterol present in various lipoprotein particles, including LDL-C, lipoprotein(a), intermediate-density lipoprotein (IDL), and very-low-density lipoprotein (VLDL) remnants [12, 13]. The non-HDLc/HDLc ratio has been demonstrated to be associated with the incidence of NAFLD in adolescents and children [14]. Furthermore, it has been shown to be a more potent marker of NAFLD than HDL-C.It is more effective than other conventional lipid parameters in assessing atherosclerosis [15, 16]. Consequently, it has been identified as a crucial target for lipid-lowering therapy [17]. Given that MASLD emphasizes the impact of metabolic disorders within the context of NAFLD, it is associated with an increased risk of cardiovascular complications. It is necessary to validate the correlation between MASLD and the non-HDLc/HDLc ratio. It is essential to further compare the predictive value of the non-HDLc/HDLc ratio with common lipid markers, such as TG, in diagnosing MASLD. Furthermore, developing lipid markers with significant diagnostic potential for predicting MASLD is crucial. Methods Data sources This retrospective study included patients who underwent physical examinations at the Health Management Centre of Guangdong Provincial Hospital of Integrative Medicine between January and December 2020. The inclusion criteria for the retrospective study were as follows: (1) Age over 18 years; (2) Underwent a general assessment, including measurements of height, weight, and blood pressure; (3) Possessed the necessary biochemical test results for the study, including fasting blood glucose, complete blood count, liver function tests, renal function tests, lipid profiles, and Hepatitis B serology; (4) Completed imaging tests such as abdominal and cardiac ultrasound; (5) Had a documented past medical history. A total of 4,656 samples met these criteria. Exclusion criteria were: (1) history of alcohol consumption exceeding 30 g/day for men or 20 g/day for women; (2)history of viral hepatitis, autoimmune hepatitis, drug-induced liver injury, toxic liver disease, or other forms of chronic liver disease; (3)history of hematological disorders; (4) history of severe renal insufficiency; and (5) insufficient clinical data. (see Annex 1). This study was approved by the Ethics Committee of Guangdong Provincial Hospital of Integrative Medicine (Ethics No. 2019 − 0218) and was conducted in accordance with the Declaration of Helsinki. Moreover, as this study was retrospective and observational in nature, the requirement for informed consent from subjects was waived. Definition and assessment of lipid indicators and MASLD The trained nurses utilized the Olympus AU-640 autoanalyzer (Olympus, Japan) to measure lipid indices, including TG, TC, LDLc, and HDLc. Additionally, the non-HDL-C/HDL-C ratio represents a novel lipid assessment index, calculated as (TC - HDLc) / HDLc. Its validity had been demonstrated in previous studies [14, 18]. In the present study, MASLD was defined as the detection of at least two abnormalities on abdominal ultrasonography [19, 20]: (1) diffuse echogenic enhancement of the liver over the kidneys or spleen; (2) posterior attenuation of the ultrasound waveforms; and (3) loss of echogenicity of the portal wall.It is associated with at least one MetS criterion: (1) BMI ≥ 25 kg/m² or WC > 94 cm (M) / 80 cm (F); (2) Fasting serum glucose ≥ 5.6 mmol/L [100 mg/dL] or 2-hour post-load glucose levels ≥ 7.8 mmol/L [≥ 140 mg/dL] or HbA1c ≥ 5.7% or type 2 diabetes or treatment for type 2 diabetes; (3) Blood pressure ≥ 130/85 mmHg or specific antihypertensive drug treatment; (4) Plasma TG ≥ 1.70 mmol/L [150 mg/dL] or lipid-lowering treatment; (5) Plasma HDL-C ≤ 1.0 mmol/L [40 mg/dL] (M) and ≤ 1.3 mmol/L [50 mg/dL] (F) or lipid-lowering treatment [21]. Additional variables The dataset included several covariates previously identified as associated with MASLD: gender, age, body mass index (BMI), blood glucose(BG), blood pressure, AST, ALT, uric acid(UA), globulin(GLB), and albumin(ALB) [22–27]. All participants were required to fast for at least eight hours prior to assessment to ensure data reliability. Statistical analysis To validate our findings, we randomly allocated the study population into two groups: a training set comprising 70% and a validation set comprising 30%. The training set was analyzed to summarize the baseline characteristics. Descriptive statistics were employed for categorical variables, presented as frequencies and percentages, while continuous variables were reported as means ± standard deviations. For between-group comparisons of the training and validation sets, continuous variables were analyzed using independent samples t-tests, while dichotomous variables were assessed with chi-square tests. In stratified intergroup comparisons focusing on the non-HDLc/HDLc ratio, continuous variables were analyzed using the ANOVA method, while dichotomous variables were evaluated with the chi-square test.When the variables were skewed, the Mann-Whitney test or the Kruskal-Wallis test was used. First, the association of each variable with MASLD was assessed using univariate logistic regression models. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated; variables deemed significant (p < 0.05) were then included in the subsequent multivariate logistic regression analyses. The models were sequentially adjusted: Model 1 included no covariates; Model 2 incorporated gender, age, and BMI; and Model 3 included variables that were significant (p < 0.05) in the univariate analyses. Interaction tests, stratified by gender, were performed based on the results of Model 3. After identifying lipid indicators associated with MASLD, we evaluated their diagnostic performance using receiver operating characteristic (ROC) analysis. The area under the curve (AUC) was used to assess the discriminatory power of the model, with an AUC closer to 1 indicating greater predictive accuracy. To enhance the model’s accuracy, we employed Decision Curve Analysis (DCA) to determine the optimal decision threshold [28]. Finally, we validated our model with a validation set to confirm its robustness. Statistical analyses were conducted using R version 4.3.3 and Empower Stats. Results Baseline characteristics Excluding 158 participants with a history of excessive alcohol consumption, viral hepatitis, autoimmune hepatitis, pharmacological liver injury, hematological disorders, severe renal insufficiency, severe organic cardiac lesions, or insufficient clinical data. In conclusion, the study included a total of 4,498 subjects (see Fig. 1). Fig. 1Flow chart for inclusion and exclusion of study participants Flow chart for inclusion and exclusion of study participants The present study was a cross sectional study test, based on the prevalence of MASLD of 0.3, a two sided test was set up with an α of 0.05. The permissible error was 0.03. Sample size of N = 928 cases was calculated using PASS 15 software. Therefore, at least 928 cases need to be included in this case as a study population(Fig. 2). Fig. 2Sample size formula Sample size formula To ensure robustness, we randomly split the dataset into a 70% training set and a 30% validation set (Supplementary Table 1). The training set included 3,149 participants, categorized into MASLD and non-MASLD groups. Results showed that individuals with MASLD were generally older, predominantly male, and had a higher BMI. They also exhibited elevated levels of ALT, AST, ALB, UA, and BG, along with an increased risk of hypertension. The lipid profile showed higher levels of LDL-C and TC, and lower levels of HDL-C, consistent with previous studies [29–31]. Additionally, patients with MASLD exhibited significantly higher non-HDLc/HDLc ratios (Table 1). Additionally, we stratified the training set population by non-HDLc/HDLc quartiles (Supplementary Table 2). As non-HDLc/HDLc ratios increased, there were corresponding increases in age, AST, ALT, UA, TC, LDL-C, ALB, TG, BG, BMI, and the prevalence of both hypertension and MASLD. A higher proportion of male patients was also observed with rising non-HDLc/HDLc ratios, while HDL levels decreased as non-HDLc/HDLc ratios increased. Table 1Baseline characteristics of participantsNon-MASLDMASLDU(χ2)p-valueN2555823Age (years)39.542 ± 12.23044.539 ± 11.711−12.047< 0.001Gender181.172*< 0.001Male (%)1110 (43.444%)601 (73.026%)Female (%)1445 (56.556%)222 (26.974%)BMI (kg/m2)23.120 ± 2.25024.664 ± 2.248−1.696< 0.001ALT (U/L)28.00 (21.00–41.00)28.00 (21.00–41.00)−16.746< 0.001AST (U/L)19.935 ± 10.25422.631 ± 9.326−7.121< 0.001GLB (g/L)25.615 ± 3.66225.642 ± 3.4890.2520.801ALB(g/L)45.773 ± 2.63946.397 ± 2.472−4.939< 0.001UA (µmol/L)336.430 ± 88.506414.623 ± 99.447−20.545< 0.001TC (mmol/L)5.457 ± 1.0255.892 ± 1.086−11.206< 0.001HDL (mmol/L)1.587 ± 0.2821.418 ± 0.24017.154< 0.001LDL (mmol/L)3.094 ± 0.7203.479 ± 0.804−11.667< 0.001non-HDLc/HDLc2.507 ± 0.7303.226 ± 0.845−26.807< 0.001TG (mmol/L)1.16 (0.80–1.44)2.21 (1.69–2.87)−28.668< 0.001BG(mmol/l)5.081 ± 0.5035.465 ± 0.749−19.740< 0.001Hypertension45.966*< 0.001Non-Hypertension (%)2507 (98.121%)785 (95.383%)Hypertension (%)48 (1.879%)38 (4.617%)ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease.*Indicates U test result Table 1Baseline characteristics of participantsNon-MASLDMASLDU(χ2)p-valueN2555823Age (years)39.542 ± 12.23044.539 ± 11.711−12.047< 0.001Gender181.172*< 0.001Male (%)1110 (43.444%)601 (73.026%)Female (%)1445 (56.556%)222 (26.974%)BMI (kg/m2)23.120 ± 2.25024.664 ± 2.248−1.696< 0.001ALT (U/L)28.00 (21.00–41.00)28.00 (21.00–41.00)−16.746< 0.001AST (U/L)19.935 ± 10.25422.631 ± 9.326−7.121< 0.001GLB (g/L)25.615 ± 3.66225.642 ± 3.4890.2520.801ALB(g/L)45.773 ± 2.63946.397 ± 2.472−4.939< 0.001UA (µmol/L)336.430 ± 88.506414.623 ± 99.447−20.545< 0.001TC (mmol/L)5.457 ± 1.0255.892 ± 1.086−11.206< 0.001HDL (mmol/L)1.587 ± 0.2821.418 ± 0.24017.154< 0.001LDL (mmol/L)3.094 ± 0.7203.479 ± 0.804−11.667< 0.001non-HDLc/HDLc2.507 ± 0.7303.226 ± 0.845−26.807< 0.001TG (mmol/L)1.16 (0.80–1.44)2.21 (1.69–2.87)−28.668< 0.001BG(mmol/l)5.081 ± 0.5035.465 ± 0.749−19.740< 0.001Hypertension45.966*< 0.001Non-Hypertension (%)2507 (98.121%)785 (95.383%)Hypertension (%)48 (1.879%)38 (4.617%)ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease.*Indicates U test result Baseline characteristics of participants ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease.*Indicates U test result Univariate analysis We conducted univariate analyses to assess the relationship between various factors and MASLD (Table 2). The results indicated that the prevalence of MASLD was higher among males and individuals with hypertension. Age, ALT, AST, UA, TC, TG, LDL-C, non-HDLc/HDLc, ALB, BG, and BMI were positively correlated with MASLD, while HDL-C showed a negative correlation (all p < 0.05). GLB was not significantly associated with MASLD (p > 0.05). Table 2Correlations between exposure factors and MASLDStatisticsOR(95% CI)p-valueAge (years)40.902 ± 12.5221.041 (1.034, 1.049)< 0.001Gender< 0.001Male (%)1629 (51.731%)1.0Female (%)1520 (48.269%)0.261 (0.213, 0.321)BMI (kg/m2)23.491 ± 2.3911.598 (1.509, 1.691)< 0.001ALT (U/L)24.124 ± 17.7341.039 (1.033, 1.045)< 0.001AST (U/L)20.594 ± 8.9961.030 (1.021, 1.040)< 0.001GLB (g/L)25.699 ± 3.6550.997 (0.973, 1.021)0.801ALB(g/L)45.913 ± 2.6571.089 (1.052, 1.126)< 0.001UA (µmol/L)357.166 ± 97.5241.009 (1.008, 1.010)< 0.001TC (mmol/L)5.575 ± 1.0701.553 (1.430, 1.687)< 0.001HDL (mmol/L)1.538 ± 0.2810.034 (0.022, 0.052)< 0.001LDL (mmol/L)3.191 ± 0.7821.891 (1.687, 2.119)< 0.001non-HDLc/HDLc2.711 ± 0.8304.129 (3.621, 4.708)< 0.001TG (mmol/L)1.497 ± 1.1134.051 (3.554, 4.619)< 0.001BG(mmol/l)5.169 ± 0.5973.782 (3.208, 4.459)< 0.001Hypertension0.001Non-Hypertension (%)3059 (97.142%)1.0Hypertension90 (2.858%)3.930 (2.572, 6.007)OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Table 2Correlations between exposure factors and MASLDStatisticsOR(95% CI)p-valueAge (years)40.902 ± 12.5221.041 (1.034, 1.049)< 0.001Gender< 0.001Male (%)1629 (51.731%)1.0Female (%)1520 (48.269%)0.261 (0.213, 0.321)BMI (kg/m2)23.491 ± 2.3911.598 (1.509, 1.691)< 0.001ALT (U/L)24.124 ± 17.7341.039 (1.033, 1.045)< 0.001AST (U/L)20.594 ± 8.9961.030 (1.021, 1.040)< 0.001GLB (g/L)25.699 ± 3.6550.997 (0.973, 1.021)0.801ALB(g/L)45.913 ± 2.6571.089 (1.052, 1.126)< 0.001UA (µmol/L)357.166 ± 97.5241.009 (1.008, 1.010)< 0.001TC (mmol/L)5.575 ± 1.0701.553 (1.430, 1.687)< 0.001HDL (mmol/L)1.538 ± 0.2810.034 (0.022, 0.052)< 0.001LDL (mmol/L)3.191 ± 0.7821.891 (1.687, 2.119)< 0.001non-HDLc/HDLc2.711 ± 0.8304.129 (3.621, 4.708)< 0.001TG (mmol/L)1.497 ± 1.1134.051 (3.554, 4.619)< 0.001BG(mmol/l)5.169 ± 0.5973.782 (3.208, 4.459)< 0.001Hypertension0.001Non-Hypertension (%)3059 (97.142%)1.0Hypertension90 (2.858%)3.930 (2.572, 6.007)OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Correlations between exposure factors and MASLD OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Association of lipid indices with MASLD To minimise confounding, we included indicators that were significant on a single factor (p < 0.05) in the multifactor logistic model for analysis. Model 1 was unadjusted, model 2 was adjusted for age, gender and BMI, and model 3 was further adjusted for ALT, AST, ALB, UA, BG and hypertension based on model 2. The results from the fully adjusted model indicated the following associations: non-HDLc/HDLc (OR = 2.709, 95% CI: 2.316–3.169), LDL-C (OR = 1.294, 95% CI: 1.125–1.489), TG (OR = 2.854, 95% CI: 2.473–3.293), and TC (OR = 1.242, 95% CI: 1.122–1.374). In all models, non-HDLc/HDLc, LDL-C, TG, and TC consistently showed positive associations with MASLD (p < 0.001). Conversely, HDL-C exhibited a negative association with MASLD (OR = 0.074, 95% CI: 0.044–0.123) (Table 3). This finding prompted further investigation into the predictive value of non-HDLc/HDLc in MASLD compared to conventional lipid markers. Table 3Relationship between non-HDLc/HDLc and common lipid and MASLD in different modelsVariableModel 1Model 2Model 3OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-valuenon-HDLc/HDLc4.129 (3.621, 4.708)< 0.0013.207 (2.778, 3.704)< 0.0012.709 (2.316, 3.169)< 0.001LDL-c1.891 (1.687, 2.119)< 0.0011.489 (1.314, 1.687)< 0.0011.294 (1.125, 1.489)< 0.001TG4.051 (3.554, 4.619)< 0.0013.267 (2.855, 3.738)< 0.0012.854 (2.473, 3.293)< 0.001TC1.553 (1.430, 1.687)< 0.0011.362 (1.242, 1.493)< 0.0011.242 (1.122, 1.374)< 0.001HDL-c0.034 (0.022, 0.052)< 0.0010.069 (0.044, 0.109)< 0.0010.074 (0.044, 0.123)< 0.001Model 1 was adjusted for: noneModel 2 was adjusted for: gender, age, BMIModel 3 was adjusted for: gender, age, BMI, ALT; AST; UA; ALB; BG; HypertensionOR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Table 3Relationship between non-HDLc/HDLc and common lipid and MASLD in different modelsVariableModel 1Model 2Model 3OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-valuenon-HDLc/HDLc4.129 (3.621, 4.708)< 0.0013.207 (2.778, 3.704)< 0.0012.709 (2.316, 3.169)< 0.001LDL-c1.891 (1.687, 2.119)< 0.0011.489 (1.314, 1.687)< 0.0011.294 (1.125, 1.489)< 0.001TG4.051 (3.554, 4.619)< 0.0013.267 (2.855, 3.738)< 0.0012.854 (2.473, 3.293)< 0.001TC1.553 (1.430, 1.687)< 0.0011.362 (1.242, 1.493)< 0.0011.242 (1.122, 1.374)< 0.001HDL-c0.034 (0.022, 0.052)< 0.0010.069 (0.044, 0.109)< 0.0010.074 (0.044, 0.123)< 0.001Model 1 was adjusted for: noneModel 2 was adjusted for: gender, age, BMIModel 3 was adjusted for: gender, age, BMI, ALT; AST; UA; ALB; BG; HypertensionOR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Relationship between non-HDLc/HDLc and common lipid and MASLD in different models Model 1 was adjusted for: none Model 2 was adjusted for: gender, age, BMI Model 3 was adjusted for: gender, age, BMI, ALT; AST; UA; ALB; BG; Hypertension OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; UA, uric acid; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALB, albumin; TG, triglyceride; BG, bloodglucose; BMI, body mass index; MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease Subgroup analysis The subgroup analyses shown in Fig. 3 examined the relationship between lipid indices and MASLD by gender, adjusting for covariates as outlined in Model 3. Notably, the interaction results indicated that gender did not affect the relationship between lipid indices and MASLD, further confirming the robustness of our findings (p for interaction > 0.05). Fig. 3Subgroup analysis Subgroup analysis Construction and validation of MASLD prediction model using lipid metrics We formed a combination of lipid indicators (non-HDL-C/HDL-C, HDL-C, LDL-C, TG, and TC) and analyzed the effectiveness of individual lipid indicators versus the combined indicators in predicting MASLD. The obtained data were also compared to evaluate their degree of effectiveness.Among others, the ROC curves illustrated the predictive abilities of non-HDL-C/HDL-C, HDL-C, LDL-C, TC, TG, and the combined markers (non-HDL-C/HDL-C + HDL-C + LDL-C + TG + TC) (Fig. 4). The metrics, including AUC, cut off, accuracy, specificity, and sensitivity, were listed in Table 4, and the DCA curves were presented in Fig. 5. ROC analyses revealed that among the individual lipid metrics, non-HDL-C/HDL-C was second only to TG in predicting the risk of MASLD. Interestingly, the combination of the metrics (non-HDL-C/HDL-C + HDL-C + LDL-C + TG + TC) yielded the highest AUC value of 0.857, suggesting that its predictive performance was superior to that of the individual metrics. To verify the accuracy of the model, we applied it to a separate validation set using the same predictor variables (Figs. 6 and 7; Table 5). The results of the validation set confirmed that the combined metric of non-HDLc/HDLc + HDL-C + LDL-C + TG + TC maintained the highest AUC (0.855). Non-HDLc/HDLc remained one of the important predictors, which was consistent with the results from the training set. Fig. 4The ROC curve of the diagnostic efficiency of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the training set The ROC curve of the diagnostic efficiency of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the training set Fig. 5Decision curve analysis (DCA) of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the training set Decision curve analysis (DCA) of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the training set Table 4Areas under the receiver operating characteristic curves for each evaluated parameter in identifying MASLDAUCCut off95%CI low95%CI uppAccuracySpecificitySensitivityJoint Lipid Indicators0.8570.1540.8400.8730.7690.7550.828TC0.6495.9550.6230.6740.7050.7520.504HDL-c0.7261.4350.7040.7480.7130.7330.626LDL-c0.6563.3450.6310.6820.6980.7350.543non-HDLc/HDLc0.8012.9680.7810.8200.7470.7520.723TG0.8481.6670.8300.8660.8340.8510.761AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Table 4Areas under the receiver operating characteristic curves for each evaluated parameter in identifying MASLDAUCCut off95%CI low95%CI uppAccuracySpecificitySensitivityJoint Lipid Indicators0.8570.1540.8400.8730.7690.7550.828TC0.6495.9550.6230.6740.7050.7520.504HDL-c0.7261.4350.7040.7480.7130.7330.626LDL-c0.6563.3450.6310.6820.6980.7350.543non-HDLc/HDLc0.8012.9680.7810.8200.7470.7520.723TG0.8481.6670.8300.8660.8340.8510.761AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Areas under the receiver operating characteristic curves for each evaluated parameter in identifying MASLD AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Fig. 6The ROC curve of the diagnostic efficiency of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the validation set The ROC curve of the diagnostic efficiency of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the validation set Fig. 7Decision curve analysis (DCA) of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the validation set Decision curve analysis (DCA) of Joint Lipid Indicator, TG, non-HDLc/HDLc ratio, HDL-C, LDL-C, TC in the validation set Table 5Validation of the area under the receiver operating characteristic curve for each assessed parameter when centrally identifying MASLDAUCcut off95%CI low95%CI uppAccuracySpecificitySensitivityJoint Lipid Indicators0.8550.1410.8280.8830.7660.7540.822TC0.6535.7100.6120.7660.6670.6770.618HDL-c0.7281.4350.6910.7010.7280.7490.627LDL-c0.6603.1790.6190.8440.6360.6360.636non-HDLc/HDLc0.8142.8160.7840.8770.7460.7370.791TG0.8481.6290.8190.8830.8400.8580.751AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Table 5Validation of the area under the receiver operating characteristic curve for each assessed parameter when centrally identifying MASLDAUCcut off95%CI low95%CI uppAccuracySpecificitySensitivityJoint Lipid Indicators0.8550.1410.8280.8830.7660.7540.822TC0.6535.7100.6120.7660.6670.6770.618HDL-c0.7281.4350.6910.7010.7280.7490.627LDL-c0.6603.1790.6190.8440.6360.6360.636non-HDLc/HDLc0.8142.8160.7840.8770.7460.7370.791TG0.8481.6290.8190.8830.8400.8580.751AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Validation of the area under the receiver operating characteristic curve for each assessed parameter when centrally identifying MASLD AUC, area under the curve; Joint Lipid Indicators, non-HDLc/HDLc + HDL-C + LDL-C + TG + TC; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; TG, triglyceride Discussion This study is the first to analyze non-HDLc/HDLc alongside common lipid markers to compare their predictive value for MASLD. We assessed the correlation of five lipid markers with MASLD, and the results aligned with previous findings [18]. Subgroup analyses further confirmed the robustness of our results (p-interaction > 0.05). We examined the diagnostic efficacy of common lipid markers versus combined lipid markers (non-HDLc/HDLc + HDL-C + LDL-C + TG + TC) in patients with MASLD. The results indicated that the combined metrics (non-HDLc/HDLc + HDL-C + LDL-C + TG + TC) were the most effective for this purpose. Validation was then performed using a dataset, which produced consistent findings. Therefore, the combined indicator may be useful for the early identification of MASLD in the Chinese population. NAFLD is the leading cause of liver-related deaths worldwide and is associated with an increased risk of both intrahepatic and extrahepatic cancers. Studies have demonstrated independent associations between NAFLD, metabolic syndrome (MetS), and an elevated risk of colorectal tumors and cancers [32–34]. In recent years, MASLD has increasingly replaced NAFLD due to the rising prevalence of obesity and metabolic syndrome. MASLD highlights the significance of cardiometabolic risk factors. A study in China found that more than 99.5% of patients with NAFLD met the criteria for MASLD [35], while the European LITMUS study reported that 98% of previous NAFLD cases met MASLD criteria [21]. Thus, the majority of previously defined NAFLD patients are now encompassed by MASLD and its subcategories, which may reflect the global impact of MASLD [36]. Previous studies have demonstrated a strong correlation between dyslipidemia and liver disease. The development of MASLD is thought to arise from metabolic dysfunction and dyslipidemia [37], characterized by the accumulation of lipids not only in adipose tissue but also in organs such as the live [38].Patients with MASLD are characterized by insulin resistance, which is associated with increased hepatic free fatty acids. Overall, patients with MASLD exhibit an imbalance in hepatic lipid metabolism, characterized by increased lipogenesis, reduced fatty acid oxidation, and decreased LDL output [39]. Excess cellular cholesterol and activation of hepatic X receptors promote the secretion of VLDLs, which in turn lead to the synthesis of small, dense LDLs. The deposition of oxidized LDLs, free cholesterol, trans fatty acids, and other lipids in the liver activates pro-inflammatory factors, leading to hepatic inflammation and further exacerbating insulin resistance [40, 41]. Additionally, the progression of inflammation in liver tissue can lead to apoptosis and abnormal hepatocyte proliferation, causing hepatocellular injury and ultimately resulting in hepatocellular carcinoma [42]. The global incidence of MASLD-associated fibrosis is rapidly increasing and is strongly linked not only to type 2 diabetes, obesity, and other cardiometabolic risk factors but also to a heightened risk of cardiovascular events and intrahepatic and extrahepatic malignancies. The implications present not only a challenge to global health but also impose significant socio-economic burdens, underscoring the importance of early identification of MASLD. Strengths and limitations The results of this study have important clinical implications. First, the correlation between the non-HDLc/HDLc ratio and MASLD was confirmed. Additionally, this is the first study to compare the predictive value of the non-HDLc/HDLc ratio with conventional lipid indices for MASLD. The findings indicated that the combined lipid indices predicted MASLD more effectively than individual lipid indices. The non-HDLc/HDLc ratio is derived from conventional lipid screening results, highlighting the simplicity and feasibility of the assay. Therefore, the combined lipid index (non-HDLc/HDLc + HDL-C + LDL-C + TG + TC) may help identify MASLD in the Chinese population while reducing the additional costs associated with its detection. However, several limitations should be noted. First, the cross-sectional design of the study limits the ability to establish causality, focusing only on correlation. Second, although liver ultrasonography was used to detect fatty liver, its sensitivity decreases when body fat percentage is below 30%, potentially leading to misdiagnosis [43]. Liver biopsy remains the gold standard for diagnosing MASLD, as it can detect mild hepatic steatosis that is undetectable by ultrasonography [44]. Third, despite our efforts to account for numerous confounders in our analyses, residual confounding may still be present. Fourth, since MASLD is a broad term for fatty liver, the study did not clarify the relationship between lipid markers and the different stages of fatty liver. Finally, as this study focused exclusively on the Chinese population, further investigation in larger and more diverse cohorts is necessary to generalize these findings to other ethnic groups. Conclusion The results of this cross-sectional study involving Chinese adults demonstrated a positive correlation between the non-HDLc/HDLc ratio and MASLD. Moreover, the non-HDLc/HDLc ratio exhibited strong predictive power in identifying MASLD, while the combined lipid metrics (non-HDLc/HDLc + HDL-C + LDL-C + TG + TC) provided the highest predictive capability. Data Availability All data generated or analysed in this study are included in this published article. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3